HUGO-Light™ Fully Human Common Light Chain Mouse for Bispecific & Multispecific Antibody Development

HUGO-Light™ is a fully human common light chain antibody mouse platform designed to simplify bispecific antibody discovery by fixing the light chain while preserving extensive heavy-chain variable-region diversity. The platform supports efficient generation of common-light-chain antibody candidates with strong in vivo immune responses, streamlined pairing logic, and direct compatibility with downstream bispecific antibody assembly strategies.

Overcoming the Bispecific Antibody Manufacturing Bottleneck

In the rapidly evolving landscape of bispecific antibody (bsAb) therapeutics, correct chain pairing remains a critical manufacturing challenge. While steric complementarity-based technologies like Knobs-into-Holes (KiH) have effectively addressed heavy chain mispairing—achieving 90-95% correct assembly —they do not resolve the light chain mispairing issues that lead to unwanted homodimeric byproducts.

To overcome this barrier, Cyagen has engineered the HUGO-Light™ Fully Human Common Light Chain Mouse. By combining a single, fixed human kappa light chain with highly diverse, full-length human heavy chain variable region genes, our platform fundamentally prevents light chain mispairing. When integrated with established technologies like KiH, HUGO-Light™ offers a highly efficient, streamlined strategy for producing pure, fully human bispecific antibodies.

HUGO-Light™: Engineered for Bispecific Antibody Discovery

The HUGO-Light™ mouse is a genetically engineered mouse model designed to produce humanized antibodies featuring a common light chain. Through precise genetic modification, all generated antibodies share an identical light chain, a structural design highly applicable for the development of bispecific or multispecific antibodies.The HUGO-Light™ Fully Human Common Light Chain Antibody Mouse takes this a step further, generating fully human antibodies in vivo with exceptional affinity and reduced immunogenicity risk. By significantly accelerating both antibody discovery and novel therapeutic R&D pipelines, the HUGO-Light™ platform has earned rigorous validation and trust from multinational pharmaceutical corporations, innovative biotechs, and leading academic research institutions worldwide.

Strain Name: Fully Human Common Light Chain Antibody Mouse

Strain Abbreviation: HUGO-Light™

Genetic Background: C57BL/6NCya、BALB/cAnCya

Coat Color: Black, White

Application: Development of fully human fixed-light chain monoclonal antibodies

Explore Our Antibody Bluebook

Schematic Representation of the Antibody Gene Structure in HUGO-Light™ Mice

HUGO-Light™ mice are constructed using a three-component antibody gene strategy:

The heavy chain is derived from the HUGO-Mab™ platform, with complete human V, D, and J variable-region genes inserted to support broad heavy-chain repertoire diversity.
The κ light-chain locus is engineered via Cyagen’s TurboKnockout™ ES cell targeting technology, resulting in a fixed human-derived VJ variable-region combination.
The λ light-chain locus is completely deleted to restrict antibody generation to the engineered κ common light chain.

Figure 1. Schematic Representation of the Antibody Gene Structure in HUGO-Light™ Mice.

Key Features

Engineered Common Light Chain

Utilizes a single, pre-fixed human κ light chain to completely eliminate light-chain mispairing, while maximizing fully human heavy-chain repertoire diversity for efficient bispecific antibody development.

Robust In Vivo Immune Response

Maintains a fully intact murine constant region to ensure robust in vivo immune responses, consistently delivering high-titer serum against complex antigens.

Preserved B-Cell Maturation

Exhibits physiological T, B, and NK cell population profiles, ensuring a highly diverse and reliable B-cell pool optimized for downstream single B-cell screening workflows.

Bispecific Engineering Compatibility

Retains native antibody structural integrity, generating premium therapeutic antibody candidates with superior binding affinity, robust developability, and preserved physiological effector activities.

HUGO-Light™ Common Light Chain Strain Library

Model ID	Background	Engineering Strategy	Heavy Chain Variable Region (VH)	Light Chain Lambda (λ)	Light Chain (IgK / IgL)
Model ID	Background	Engineering Strategy	Heavy Chain Variable Region (VH)	Light Chain Lambda (λ)	Kappa V Region	Kappa J Region	Kappa C Region	Targeted Locus
1	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV1-39	Human-derived IGKJn	mouse	Kappa
2	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV3-20	Human-derived IGKJn	mouse	Kappa
3	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived GKV1-5	Human-derived IGKJn	mouse	Kappa
4	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV1-33	Human-derived IGKJn	mouse	Kappa
5	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV2-28	Human-derived IGKJn	mouse	Kappa
6	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV4-1	Human-derived IGKJn	mouse	Kappa
7	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV3-15	Human-derived IGKJn	mouse	Kappa
8	C57	ES Cell Targeting	Fully Human FL	knock-out	Human-derived IGKV3-11	Human-derived IGKJn	mouse	Kappa
9	C57	ES Cell Targeting	Fully Human FL	knock-out	IGKV1-39, 2-28, 3-20, 4-1	Human-derived IGKJn	mouse	Kappa
10	C57	ES Cell Targeting	Fully Human FL	knock-out	IGKV1-33, 2-30, 3-15, 3-11	Human-derived IGKJn	mouse	Kappa

Immunization Recommendations

Suggested Immunization Age: 6-8 weeks

Health Status: Specific Pathogen Free (SPF)

Product Advantage

Precision Engineering via TurboKnockout™: Built on Cyagen’s proprietary ES cell targeting technology, ensuring precise, footprint-free genetic modifications with unparalleled genomic stability.
Extensive Common-Light-Chain Library: Offers a robust selection of strains built around the most frequently utilized human kappa light-chain germlines, maximizing your target-specific screening flexibility.
Uncompromised Heavy-Chain Diversity: Retains a fully human, highly diverse heavy-chain variable-region repertoire to drive the generation of rare, high-affinity therapeutic candidates.
Dual Genetic Backgrounds: Available in both C57BL/6 and BALB/c strains to effectively break immune tolerance and accommodate diverse, highly challenging immunization strategies.

HUGO-Light™ mice can generate fully humanized antibodies in vivo with high affinity and low immunogenicity, demonstrating superior functional activity compared to FDA-approved standard therapies.

{{v2}}

{{item}}

Common Light-Chain Workflow for Bispecific and Multispecific Antibody Development

HUGO-Light™ is designed to streamline bispecific and multispecific antibody development by generating fully human antibody candidates that share a fixed human κ common light chain. Target-specific heavy chains identified from the platform can be recombinantly expressed, functionally screened, and further reformatted into IgG-like bispecific antibodies using established heavy-chain heterodimerization strategies. This workflow reduces light-chain pairing complexity while preserving antibody diversity for downstream lead discovery and engineering.

Common Light-Chain Antibody Discovery

Target-specific antibodies are generated from HUGO-Light™ mice using a fixed human κ common light chain and diverse human heavy-chain repertoires.

Anti-PD-1 Antibody

Anti-VEGF Antibody

Heavy-Chain Selection & Reformatting

Selected heavy-chain variable regions are paired with the shared human κ light chain and recombinantly expressed for downstream screening.

● Anti-PD-1 heavy chain

● Anti-VEGF heavy chain

● Shared human κ light chain

Bispecific Assembly with KiH

When integrated with KiH or other heterodimerization technologies, common light-chain antibodies support cleaner IgG-like bispecific antibody assembly.

Anti-PD-1 & VEGF Bispecific Antibody

Integrated Antibody Discovery Workflow for Bispecific and Multispecific Development

Built on the HUGO-Light™ common light-chain platform, Cyagen provides an end-to-end workflow to help accelerate the generation of fully human common light-chain antibody candidates for bispecific and multispecific antibody development.

STEP 01

Optimized Immunization

Protein, cell-based, DNA, or mRNA-LNP antigen formats tailored to the target biology and discovery objective.

STEP 02

Single B-Cell Screening

Isolation and screening of antigen-specific B cells to identify target-binding antibody candidates.

STEP 03

Sequencing & Recombinant Expression

Recovery of heavy-chain sequences paired with the fixed human κ light chain

STEP 04

In Vitro Characterization

Binding, specificity, affinity, internalization, and functional assays using ELISA, FACS, BLI, and cell-based readouts.

STEP 05

Bispecific Assembly & Validation

Integration with KiH or other bispecific engineering strategies to support IgG-like bsAb assembly and downstream validation.

Case Studies

{{v2}}

{{item}}

Our Unique Advantages

Precision-Engineered Common Light-Chain Platform

Built on Cyagen’s proprietary TurboKnockout™ ES cell targeting technology, HUGO-Light™ enables precise, footprint-free genetic modification with stable genomic integration. The platform is designed to support reliable generation of fully human common light-chain antibody candidates for downstream bispecific and multispecific antibody development.

Multiple Genetic Backgrounds for Flexible Immunization Strategies

Available in both C57BL/6 and BALB/c backgrounds, HUGO-Light™ supports flexible immunization strategies for diverse antigen formats and challenging therapeutic targets.

Related Resources

Events & Webinars

Life Science Exhibits at UC San Francisco - Mission Bay

View Details

Promotional Campaign

Flash Drop — Ready-to-Ship KO/cKO Mice

View Details

Blogs & Insights

Advancing C5AR1 Drug Development in 2026: How Humanized Mouse Models Support Next-Generation C5AR1 Antagonists

View Details

Resource Valut

Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders

View Details

Request a Preclinical CRO Services Consultation

Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.